22 results about "Human bladder" patented technology

The invention discloses a paris polyphylla extract which is prepared by the following steps: extracting crushed paris polyphylla for 1-3 times by adopting a cyclodextrin solution at 30-70 DEG C under ultrasonic waves, collecting and combining an extracting solution, separating and purifying the extracting solution through macroporous resin, eluting the extracting solution through an ethanol solution with the volume concentration of 70%, and concentrating and drying the eluent, thereby obtaining the paris polyphylla extract. The paris polyphylla extract is applied to treatment of bladder cancer, experimental results show that the paris polyphylla extract has an obvious inhibiting effect on proliferation of human bladder cancer cells T24 and UM-UC-3, a theoretical basis is provided for deep research on the anti-tumor action mechanism of paris polyphylla, and the paris polyphylla extract is of great significance in revealing research on anti-tumor effective active ingredients of paris polyphylla and has a wide application prospect. The invention provides a new way and means for treating tumors.

The invention provides a human bladder cancer vedicetumab drug-resistant cell strain as well as a construction method and application thereof. The cell strain is named as a human bladder cancer drug-resistant cell strain T24-RC48, and the preservation number of the cell strain is CCTCC (China Center For Type Culture Collection) NO: C2024180. During construction, a method of continuously inducing at low concentration and gradually increasing the drug concentration and the treatment time of the RC48 is adopted, so that the formation of the RC48 drug-resistant cells is effectively induced, and the construction method is simple to operate and can effectively make up for the defects of the existing method. The human bladder transitional cell carcinoma RC48 drug-resistant cell strain T24-RC48 constructed by the invention can be used for researching a bladder cancer drug-resistant mechanism, promoting the development of predictive biomarkers, evaluating the antitumor activity of drugs and preparing a tumor cell model or a tumor animal model; a cell research model is provided for screening, researching and developing effective drugs and methods for overcoming bladder cancer drug resistance, and good application prospects are achieved.

Provided are a heteroaromatic ring compound represented by formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof. The heteroaromatic ring compound has good inhibitory activity and selectivity on FGFR2 abnormity, and compared with human small cell lung cancer cells DMS114 and human bladder cancer cells RT112 / 84, the heteroaromatic ring compound shows good proliferation inhibitory activity on human gastric cancer cells SNU-16. The heteroaromatic ring compound can be well absorbed after oral administration, and has good drug exposure in a rat body.

The invention belongs to the technical field of biomedicine, and relates to a human bladder cancer cell line ZSZB1 with primary cis-platinum drug resistance and application thereof. The cell line is preserved in the China Center for Type Culture Collection (CCTCC), the preservation number is CCTCC No: C2024120, and the cell line is derived from a radical operation specimen of primary chemotherapy drug-resistant bladder cancer patients of Chinese population, and has stable in-vitro multiplication capacity and primary cis-platinum drug-resistant characteristic. The ZSZB1 provides an ideal experimental model for bladder cancer pathogenesis research, cis-platinum drug resistance mechanism exploration and novel antitumor drug screening. Establishment of the cell line can effectively promote transformation from basic research of bladder cancer to clinical application, and the cell line is of great significance to promotion of precise medical development.

The application is a urethral catheter with conductive structure, which comprises a flexible catheter, the flexible catheter enters the human bladder through the urethra, the outer surface of the flexible catheter is partially provided with a conductive structure, the conductive structure is arranged at the prostate part of the outer distal end of the flexible catheter to assist freezing and electric ablation, the flexible catheter is internally provided with a liquid guide channel and a liquid guide opening is arranged at the distal end of the flexible catheter, the urethral catheter has a temperature protection effect, a temperature protection channel is divided into a liquid inlet channel and a liquid outlet channel by an inner sleeve and an outer sleeve, a surface electrode on the outer wall of the inner sleeve is connected to the circuit of a host, and the conductive structure only conducts electricity and does not have an electrochemical reaction. The application is used for cooperating to complete electric effect or electric ablation diagnosis and treatment effect and freezing, radio frequency and microwave and other thermal ablation, can avoid cold and hot damage or electric damage to the urethra or the prostate, has a temperature adjusting function and a simple structure and is easy to adjust and control.

The invention discloses a bladder tumor cell strain with squamous differentiation characteristics and application thereof, and relates to the technical field of biological medicines. Wherein the bladder tumor cell strain is selected from one of a human bladder tumor cell strain MP-MGHU3-LT, a human bladder tumor cell strain UCSD-MGHU3-LT, a human bladder tumor cell strain UCSD-RT4-LT and a mouse bladder tumor cell strain mUCMP, the bladder tumor cell strains are all preserved in the China Center for Type Culture Collection, and the preservation numbers of the bladder tumor cell strains are respectively CCTCC NO: C2025241, CCTCC NO: C2025252, CCTCC NO: C2025253 and CCTCC NO: C2025254. The bladder tumor cell strain provided by the invention has squamous differentiation characteristics, and can be applied to model construction, mechanism research and drug screening of bladder cancer with squamous differentiation characteristics.

The invention discloses a piperazinyl modified quinazolinyl-aryl urea derivative as well as a preparation method and application thereof, and relates to the field of medicines. According to the piperazinyl-modified quinazolinyl-aryl urea derivative, two pharmacophores of 4-amino quinazolinyl and ureido are connected by adopting benzyl as an intermediate chain, phenyl, substituted phenyl, benzyl or naphthenic base is connected to the ureido, alkoxy is connected to the quinazoline ring 6-site, and # imgabs0 # cancer inhibition activity is high. The demethylation reagent used in the synthetic route can efficiently and selectively remove 6-position methyl of the intermediate 2, and the yield is high. A plurality of synthesized compounds show a good proliferation inhibition effect on cell lines such as human bladder cancer, osteosarcoma, pancreatic cancer and hepatoblastoma, show good tumor inhibition activity in a tumor-bearing nude mouse model, have the potential to become tumor molecular targeting drugs, have good water solubility and fat solubility, are suitable for various drug administration modes, and have wide application prospects. And the bioavailability is improved after modification.

Bladder pressure measuring equipment comprises a liquid inlet device, the liquid inlet device comprises a liquid inlet pipe, one end of the liquid inlet pipe is connected with a first three-way pipe, the first three-way pipe is further connected with a pressure measuring device and an infusion device, the infusion device comprises an infusion pipe, and the pressure measuring device comprises a pressure measuring pipe with scale marks. The zero graduation line of the pressure measuring tube is kept consistent with the symphysis pubis horizontal plane of a patient, liquid flows through the infusion device from the liquid inlet device, then enters the bladder of the human body and then flows back to the pressure measuring device, measured values can be read by reading the horizontal height of the liquid in the pressure measuring tube, a pressure measuring ruler is not needed, operation steps are simplified, and working efficiency is improved. The reading accuracy is improved, and the department cost is reduced. The floating ball is arranged in the pressure measuring tube, the center of the floating ball is coplanar with the zero graduation line of the pressure measuring tube before liquid enters the pressure measuring tube, the floating ball can change along with the change of the horizontal plane of the liquid after the liquid enters the pressure measuring tube, and the pressure condition of the bladder of a patient can be known by observing the position of the floating ball.

The application belongs to the technical field of medicine preparation, and particularly relates to application of leaf alcohol in preparation of urinary system tumor medicine. Through animal experiment verification, the leaf alcohol has a significant improvement effect on tumors caused by human bladder cancer cells, and can be used for treatment of urinary system tumors. The application first determines that the leaf alcohol has an inhibitory effect on proliferation, migration ability and invasion ability of urinary system tumor cells.

This invention provides a bladder tumor organoid, its culture method, and its applications, belonging to the field of organoid culture technology. The invention involves mixing bladder tumor tissue with a human bladder tumor organoid culture medium to obtain a cell suspension. This cell suspension is then cultured in an ultra-low adsorption cell culture plate to obtain bladder tumor organoids. This culture method utilizes an ultra-low adsorption cell culture plate, enabling the suspension culture of bladder tumor organoids in a liquid culture medium. The culture method described in this invention achieves rapid culture of human bladder tumor organoids, improving the culture success rate. Furthermore, the obtained human bladder tumor organoids can be digested and stably passaged.

The present application relates to the field of biotechnology, in particular to human bladder tissue digestion solution and application thereof.The digestion method of the present application can dissociate human bladder tissue cells while keeping the cell viability at more than 90%, and the amount of harvested cells is also obviously improved.Sufficient cell amount is the prerequisite for optimization treatment such as red blood cell lysis and dead cell removal.The single cell suspension obtained by the method has high viability, low clumping rate, high nucleated rate and less impurities, which can provide a basis for obtaining high-quality gene expression data in human bladder tissue single cell sequencing experiment.The present application can quickly obtain human bladder tissue primary cell suspension (sufficient cell amount, high viability, low clumping rate and less impurities) meeting the requirements of single cell experiment within 2-4 hours.

The present application relates to a kind of preparation of new indole camptothecin derivatives and its use in antitumor, the structure of the compound general formula is shown as follows.In vitro cytotoxic activity screening results show that new indole camptothecin derivatives have broad-spectrum antitumor activity, to human hepatoma cell (HepG2), human non-small cell lung cancer cell (A549), human colon cancer cell (SW480), human intrahepatic cholangiocarcinoma cell (RBE), human breast cancer cell (MCF-7), human pancreatic cancer cell (BxPC3), human bladder cancer cell (T24), human bladder cancer cell (umuc3) show strong inhibitory activity. Among them, the antitumor activity of compound D-18 is most outstanding, and shows strong inhibition to the 8 tumor cell lines measured, IC 50 The range is 0.2585-10.69 μM, significantly better than the control drug irinotecan, and comparable to topotecan activity. Therefore, indole camptothecin derivatives are expected to be developed into a new antitumor drug.

The utility model discloses a kind of for bladder washing set, belong to medical instrument technical field. Including with urethra physiological bending compliance washing pipe, washing pipe is opened in and goes liquid passage, washing pipe head is opened with the side hole that goes liquid passage is communicated, washing pipe tail is provided with liquid supply component and washing component. The set is through setting with urethra physiological bending compliance washing pipe, can easily pipe body is in-depth into human bladder, by controlling three-way valve, first physiological saline is extruded into washing balloon, then make washing balloon and washing pipe communicate, extrude washing balloon, complete the washing of bladder, simultaneously, it can also be the tissue fragment in bladder, blood clot is sucked to washing balloon in side hole, it is extracted from human, convenient operation, it can be completed in bedside, greatly reduce the risk of bladder cancer electrocision patient secondary operation, strong practicality.

The present invention belongs to the field of biomedicine, and specifically relates to an siRNA, its antibody conjugate, product and application. The sense strand of the siRNA of the present invention is the sequence shown in SEQ ID NO: 17, and the antisense strand is the sequence shown in SEQ ID NO: 18; the present invention also provides an siRNA antibody conjugate prepared by a site-specific conjugation method, including an antibody, a linker and siRNA, and the siRNA is preferably a modified siRNA; the modified nucleotide is selected from one or more of 2'-position sugar moiety modification, phosphate group modification or nucleotide analogue modification. The siRNA antibody conjugate of the present invention can reduce the expression of DMPK mRNA in human skeletal muscle cells HSKMC and human bladder transitional cell papilloma cells RT4, and has great significance for the treatment of DM1 type myotonic dystrophy disease.

The invention discloses a novel application of polyphyllin VII in preparation of a medicine for enhancing ferroptosis sensitivity of human bladder cancer cells and liver cancer cells, the polyphyllin VII is combined with a GPX4 inhibitor for use, and experiments show that the polyphyllin VII can enhance the sensitivity of the bladder cancer cells to JKE and can reduce the median inhibitory concentration of the bladder cancer cells in cooperation with the JKE; when the polyphyllin VII is respectively combined with the GPX4 inhibitor JKE, ML210, RSL3 or ML162 for use, the polyphyllin VII has the effect of synergistically inhibiting the activity of liver cancer cells; the synergistic effect is dose-dependent within a certain range; the result and discovery in bladder cancer cells verify each other, and the result shows that the PPVII can be used as a broad-spectrum ferroptosis sensitizer, is not limited to bladder cancer, and also shows huge application potential in treatment of liver cancer, and the invention provides a brand-new drug combination strategy for overcoming tumor drug resistance.

The invention relates to an evodiamine analogue as well as a preparation method and application thereof, and belongs to the field of organic chemistry. A target compound is synthesized through an intramolecular hydrogen borrowing reaction by taking a 2-indolyl quinazolinone derivative as a substrate and using a nickel-based catalyst. The method is simple in route, high in yield and low in production cost. When the concentration is 1 [mu] M / L, the inhibition effects of the target compounds 1k and 1o on the proliferation of in-vitro human colon cancer cells HCT-116 are superior to that of the medicine evodiamine, and the inhibition effects of the target compounds 1k and 1o on the proliferation of the in-vitro human colon cancer cells HCT-116 are equivalent to that of the medicine In addition, the inhibition effects of the compounds 1d, 1k and 1o on proliferation of in-vitro human bladder cancer cells T24 are better than those of evodiamine; it shows that part of target compounds have potential medicinal values.

The invention relates to the technical field of bladder cancer treatment, and particularly discloses a method for inducing necrotic apoptosis of bladder cancer cells by inhibiting ADM up-regulation of STAT1, and the method comprises the following steps: resuscitating a cell cryopreservation tube filled with a human bladder cancer cell strain T24, and then adding the cell cryopreservation tube into a complete culture medium for cell culture; when the growth density of the human bladder cancer cells reaches 80%, pancreatin is added for digestion to prepare a cell suspension, then centrifugation is performed, a supernatant is discarded, and subculture is performed after resuspension; the method comprises the following steps: preparing cells in subculture into a cell suspension, inoculating the cell suspension into a 6-well plate for culture, then discarding a culture medium, adding a 1640 culture medium, adding ADM-siRNA and LipofectamineTM3000 for transfection, collecting the cells, and detecting the apoptosis condition. According to the invention, ADM-SiRNA is transfected in bladder cancer cells to knock down the expression of ADM and up-regulate the expression of STAT1, so that an STAT1-mediated RIPK1 / RIPK3 / MLKL signal channel is activated, and bladder cancer cell apoptosis is promoted, so that the invention provides an important theoretical basis and practical guidance for developing accurate and efficient anti-tumor therapy.

The present invention provides the use of Cistancheside F or a pharmaceutically acceptable salt thereof in the preparation of an anti-tumor drug. In vitro experiments show that Cistancheside F has significant inhibitory activity against a variety of tumor strains, including human lung cancer cells A549, human gastric adenocarcinoma cells AGS-CAS9, human liver cancer cells SK-HEP-1, human bladder cancer cells RT112, human cervical cancer cells Hela, human prostate cancer cells PC-3, and human neuroblastoma cells SH-SY5Y. Animal experiments show that Cistancheside F has a good in vivo anti-tumor effect and has a significant therapeutic effect on a variety of tumors, such as bladder cancer and liver cancer. Cistancheside F has strong anti-tumor activity and has broad application prospects.

The present invention discloses a Lactiplantibacillus plantarum and its application. The Lactiplantibacillus plantarum is named strain LSA-410, which was deposited at the Guangdong Provincial Culture Collection Center of Microorganisms on August 18, 2022, with the deposit number GDMCC No. 62712. The strain LSA-410 has a strong lactic acid production ability, can effectively inhibit the growth of common pathogenic bacteria in the urogenital tract (such as Gardnerella vaginalis, uropathogenic Escherichia coli, etc.), can strongly adhere to cervical epithelium (Hela cells) and human bladder transitional cell carcinoma cells (T24 cells), is non-toxic, non-pathogenic, safe and reliable. Based on these advantages, the strain LSA-410 can be used for the research and development of vaginal microecological preparations for the treatment / prevention of urogenital diseases, and reduce the infection and recurrence rates of urogenital diseases.

The invention provides a biomarker for diagnosing bladder cancer and application of the biomarker, and by analyzing single-cell transcriptome data of normal bladder epithelial cells and bladder cancer cells, ZDHHC20 is found to be continuously increased in the process of transforming from the bladder epithelial cells to vicious cells, and is remarkably and highly expressed in human bladder cancer tissues. Functional studies show that overexpression of ZDHHC20 can significantly activate PI3K / AKT, Wnt / beta-catenin, cell cycle and other cancer-promoting signal channels, so that normal bladder epithelial cells obtain malignant growth ability independent of adherence. The results show that ZDHHC20 is an important molecule for driving the vicious transformation of bladder epithelial cells. The invention discloses a key effect of the ZDHHC20 in bladder cancer generation, and shows that the ZDHHC20 can be used as a bladder cancer diagnosis and treatment target.

The invention relates to the technical field of wearing monitoring, and discloses an intelligent wearing monitoring system, which comprises a hardware module, a software module and a user interaction module, and is characterized in that the hardware module comprises an embedded system board which comprises an STM32 microcontroller, a Bluetooth 5.0 module, a sensor and a lithium battery; the bioelectrical impedance analysis module comprises a 32-bit processor and is used for monitoring the bladder state of the patient in real time; and the electrode part adopts a low-polarization wet Ag / AgCl electrode, is bonded by using conductive adhesive and is connected with the embedded system board through a conductive wire. Based on a bioelectrical impedance technology principle, a wearable and low-power-consumption intelligent sensing device is independently designed and researched and developed by utilizing an embedded technology and a single-chip microcomputer PCB technology, real-time monitoring and diagnosis of volume change of human bladder tissue are realized, and products for monitoring bladder capacity in the market at present mainly depend on an ultrasonic technology and an optical technology, so that the volume change of the human bladder tissue can be monitored and diagnosed in real time. Produced products are large in power consumption and high in professional requirement degree, and real-time monitoring cannot be achieved.

The invention relates to the technical field of bladder irrigation, and discloses a bladder irrigation device with a constant temperature and speed control alarm function, the bladder irrigation device comprises an infusion support and a catheter body inserted into the bladder of a human body and communicated with a drainage bag, a heat preservation device is installed on the surface of the infusion support, and the heat preservation device comprises a supporting seat and a temperature control device; the supporting seat is fixed to the surface of an infusion support telescopic rod, and the top of the supporting seat is rotationally connected with a movable disc; the constant-temperature parts are fixed to the two sides of the movable disc, and the sizes of the constant-temperature parts on the two sides are matched with the size of an infusion bottle; the limiting piece II is arranged between the supporting seat and the constant-temperature part and is used for fixing the rotated constant-temperature part; after an infusion bottle is placed in the infusion plate, along with the attachment and fixation of the cover plate and the infusion plate, the infusion bottle can be heated by starting the heating piece, so that the infusion bottle can be kept in a constant-temperature state, and the bladder can be conveniently and better flushed in the follow-up process.